IN2012DN00908A - - Google Patents

Info

Publication number
IN2012DN00908A
IN2012DN00908A IN908DEN2012A IN2012DN00908A IN 2012DN00908 A IN2012DN00908 A IN 2012DN00908A IN 908DEN2012 A IN908DEN2012 A IN 908DEN2012A IN 2012DN00908 A IN2012DN00908 A IN 2012DN00908A
Authority
IN
India
Prior art keywords
polypeptides
factor
modified factor
methods
relates
Prior art date
Application number
Other languages
English (en)
Inventor
Brooks Alan
Patel Chandra
Jiang Xiaoqiao
Gritzan Uwe
Apeler Heiner
Wangjun
Original Assignee
Bayer Healthcare Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529743&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00908(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Llc filed Critical Bayer Healthcare Llc
Publication of IN2012DN00908A publication Critical patent/IN2012DN00908A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/644—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
IN908DEN2012 2009-07-31 2010-08-02 IN2012DN00908A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23055109P 2009-07-31 2009-07-31
PCT/US2010/044177 WO2011014890A1 (en) 2009-07-31 2010-08-02 Modified factor ix polypeptides and uses thereof

Publications (1)

Publication Number Publication Date
IN2012DN00908A true IN2012DN00908A (ru) 2015-04-03

Family

ID=43529743

Family Applications (1)

Application Number Title Priority Date Filing Date
IN908DEN2012 IN2012DN00908A (ru) 2009-07-31 2010-08-02

Country Status (21)

Country Link
US (1) US20120164130A1 (ru)
EP (1) EP2461821A4 (ru)
JP (1) JP2013500726A (ru)
KR (1) KR20120060209A (ru)
CN (1) CN102573890A (ru)
AU (1) AU2010278721A1 (ru)
BR (1) BR112012002072A2 (ru)
CA (1) CA2769258A1 (ru)
CL (1) CL2012000238A1 (ru)
CR (1) CR20120052A (ru)
CU (3) CU20120018A7 (ru)
DO (1) DOP2012000030A (ru)
EA (1) EA201290069A1 (ru)
EC (1) ECSP12011637A (ru)
GT (1) GT201200023A (ru)
IN (1) IN2012DN00908A (ru)
MX (1) MX2012001346A (ru)
PE (1) PE20121643A1 (ru)
SG (1) SG178119A1 (ru)
WO (1) WO2011014890A1 (ru)
ZA (1) ZA201200716B (ru)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008074032A1 (en) 2006-12-15 2008-06-19 Baxter International Inc. Factor viia- (poly) sialic acid conjugate having prolonged in vivo half-life
FI3581650T3 (fi) 2008-09-15 2023-03-23 Uniqure Biopharma B V IX-tekijän polypeptidimutantti, sen käyttöjä ja menetelmä sen valmistamiseksi
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
DK2459224T3 (en) 2009-07-27 2016-07-25 Baxalta GmbH Blodstørkningsproteinkonjugater
PL2459224T3 (pl) 2009-07-27 2017-08-31 Baxalta GmbH Koniugaty białka związanego z krzepnięciem krwi
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
KR102172133B1 (ko) * 2010-07-30 2020-11-02 박스알타 인코퍼레이티드 옥심 결합용 친핵성 촉매
HUE049352T2 (hu) 2010-12-22 2020-09-28 Baxalta GmbH Anyagok és módszerek egy vízoldható zsírsavszármazéknak egy fehérjéhez való konjugálására
DK2794665T3 (da) * 2011-12-19 2018-01-29 Dilafor Ab Ikke-antikoagulative glycosaminoglycaner omfattende disaccharid-gentagelsesenhed og medicinsk anvendelse deraf
EP2922871B1 (en) * 2012-11-20 2019-06-19 The University of North Carolina At Chapel Hill Methods and compositions for modified factor ix proteins
CA2901928C (en) * 2013-03-13 2017-10-10 Eli Lilly And Company Modified canine leptin polypeptides
TW201519900A (zh) * 2013-04-28 2015-06-01 Bayer Healthcare Llc 用於誘導對凝血因子蛋白之免疫耐受性的組成物及方法
GB201420139D0 (en) 2014-11-12 2014-12-24 Ucl Business Plc Factor IX gene therapy
TWI741992B (zh) 2015-08-03 2021-10-11 美商百歐維拉提夫治療公司 因子ｉｘ融合蛋白以及其製備及使用方法
CN109789181A (zh) * 2016-07-27 2019-05-21 费城儿童医院 用于调节因子ix功能的组合物和方法
US10842885B2 (en) 2018-08-20 2020-11-24 Ucl Business Ltd Factor IX encoding nucleotides

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030044982A1 (en) * 2001-04-25 2003-03-06 Kenneth Chien Method to treat hemophilia by hepatic gene transfer of factor VIII/IX with vesicle vector
US20060040856A1 (en) * 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
BRPI0417341A (pt) * 2003-12-03 2007-04-17 Neose Technologies Inc fator ix glicopeguilado
EP2423306A1 (en) * 2006-06-19 2012-02-29 Catalyst Biosciences, Inc. Modified coagulation factor IX polypeptides and use thereof for treatment
US7700734B2 (en) * 2007-01-09 2010-04-20 Shu-Wha Lin Recombinant human factor IX and use thereof

Also Published As

Publication number Publication date
EP2461821A4 (en) 2013-07-03
GT201200023A (es) 2014-01-27
CN102573890A (zh) 2012-07-11
EP2461821A1 (en) 2012-06-13
PE20121643A1 (es) 2012-11-25
CA2769258A1 (en) 2011-02-03
BR112012002072A2 (pt) 2016-11-08
CU20130057A7 (es) 2013-06-28
CL2012000238A1 (es) 2012-10-05
JP2013500726A (ja) 2013-01-10
CU20120018A7 (es) 2012-06-21
DOP2012000030A (es) 2012-02-29
ZA201200716B (en) 2013-07-31
WO2011014890A1 (en) 2011-02-03
CU20130058A7 (es) 2013-06-28
CR20120052A (es) 2012-06-04
US20120164130A1 (en) 2012-06-28
ECSP12011637A (es) 2012-02-29
AU2010278721A1 (en) 2012-02-16
KR20120060209A (ko) 2012-06-11
SG178119A1 (en) 2012-03-29
MX2012001346A (es) 2012-02-17
EA201290069A1 (ru) 2012-07-30

Similar Documents

Publication Publication Date Title
IN2012DN00908A (ru)
MX2011007930A (es) Conjugados de insulina cristalina.
MY192475A (en) Modified factor ix polypeptides and uses thereof
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
MX2012003723A (es) Compuestos policiclicos como antagonistas del receptor de acido lisofosfatidico.
TW201129377A (en) Binding proteins that bind to human FGFR1c, human β-Klotho and both human FGFR1c and human β-Klotho
GEP20146056B (en) Acylated glucagon analogues
MX355543B (es) Macrociclos peptidomiméticos.
WO2010034032A3 (en) Methods for preparing purified polypeptide compositions
IN2012DN03883A (ru)
IN2012DN02177A (ru)
IN2012DN00754A (ru)
MX2013009175A (es) Composiciones que comprenden acido peroxi alfa-cetocarboxilico y metodos para producirlas y usarlas.
JO3635B1 (ar) مركبات صيدلانية صلبة وطرق لانتاجها
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
MX2013000958A (es) Fabricación del inhibidor-inter-alfa (iaip) a partir de plasma.
MX356755B (es) Compuestos de tipo fumagilol y metodos para su elaboración y uso.
MX2019003619A (es) Formulaciones de bromocriptina.
MX2010010457A (es) Vectores recombinantes de rinovirus.
MX349948B (es) Proteínas inmunógenas y composiciones para el tratamiento y prevención de streptococcus agalactiae.
MX2012013875A (es) Anticuerpos de union sparc en sangre periferica y usos de los mismos.
PH12014501200A1 (en) Bacteriophage gene 3 protein compositions and use as amyloid binding agents
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
MX2011008179A (es) Peptidos para vacuna.
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma